Abbott Laboratories (ABT)
Abbott Laboratories: Q4 Earnings On The Horizon
Abbott Laboratories has been essentially flat over the last 15 months, underperforming the S&P 500's 17.5% total return. Q3 2025 results showed normalized EPS in line at $1.30, with revenue up nearly 7% year-over-year, but missing consensus by $20M. Most of the segments saw healthy increases, particularly in the International regions in Q3; hopefully, we'll see the same in Q4 next week.
Abbott (ABT) Declines More Than Market: Some Information for Investors
Abbott (ABT) closed at $121.76 in the latest trading session, marking a -1.43% move from the prior day.
Insights Into Abbott (ABT) Q4: Wall Street Projections for Key Metrics
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Abbott (ABT), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2025.
Dividend King Abbott Shows Why 52 Consecutive Increases Weren't Luck With Strong Cash Flow Coverage
Abbott Laboratories (NYSE: ABT) doesn't just pay dividends.
Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know
Abbott (ABT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Abbott (ABT) Stock Sinks As Market Gains: Here's Why
The latest trading day saw Abbott (ABT) settling at $124.64, representing a -1.02% change from its previous close.
Abbott: Not Cheap, But Built To Compound In Uncertain Markets
Abbott Laboratories is a defensive, high-quality compounder with a premium valuation justified by recurring cash flow and strong medical device platforms. Medical Devices, especially Diabetes Care (Libre), are driving over 12% segment growth, with Diabetes Care revenues surpassing $2B and growing 17%. ABT reaffirmed 2025 organic growth guidance of 7.5%–8% and EPS of $5.12–$5.18, with consistent, low-volatility earnings growth expected through 2027.
Abbott (ABT) Rises Higher Than Market: Key Facts
In the latest trading session, Abbott (ABT) closed at $126.45, marking a +1.82% move from the previous day.
Here is What to Know Beyond Why Abbott Laboratories (ABT) is a Trending Stock
Zacks.com users have recently been watching Abbott (ABT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Abbott Stock May Benefit Following Volt PFA's FDA Approval
ABT wins FDA approval for its Volt PFA System for AFib, paving the way for U.S. launches and EU expansion after earlier CE Mark clearance.
Is Trending Stock Abbott Laboratories (ABT) a Buy Now?
Zacks.com users have recently been watching Abbott (ABT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Why the Market Dipped But Abbott (ABT) Gained Today
The latest trading day saw Abbott (ABT) settling at $128.47, representing a +2.4% change from its previous close.
